A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (927 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-06-11. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lymphomatherapyhodgkincellwomen
  Phrases that lowered it: participantsefficacythe pharmacokineticsopen labelinclusive
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 121 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 23.7% (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor's past termination rate: 7.1% (lowers risk) · Sponsor's track record
• Sponsor's past trials: 226 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 209810 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 47683 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 92.4% (raises risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 8 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT01611090 · started 2012 · scored riskier than 89% of active trials completed
• Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma NCT02207062 · started 2014 · scored riskier than 67% of active trials completed
• Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma NCT02309580 · started 2015 · scored riskier than 34% of active trials completed
• A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma NCT01855750 · started 2013 · scored riskier than 55% of active trials completed
• Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma NCT03093831 · started 2016 · scored riskier than 84% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.